Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125730131 | 12573013 | 1 | I | 20160706 | 20160720 | 20160720 | EXP | GB-AUROBINDO-AUR-APL-2016-08949 | AUROBINDO | 26.00 | YR | F | Y | 120.65000 | KG | 20160720 | CN | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125730131 | 12573013 | 1 | PS | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | Oral | 20 MG, UNK | U | U | 78619 | 20 | MG | ||||||
| 125730131 | 12573013 | 2 | I | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 30 MG, UNK | U | U | 0 | 30 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125730131 | 12573013 | 1 | Gastrooesophageal reflux disease |
| 125730131 | 12573013 | 2 | Depression |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125730131 | 12573013 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125730131 | 12573013 | Drug interaction | |
| 125730131 | 12573013 | Dyspepsia | |
| 125730131 | 12573013 | Pain |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125730131 | 12573013 | 1 | 20150101 | 0 | ||
| 125730131 | 12573013 | 2 | 20150101 | 0 |